Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia



Status:Active, not recruiting
Conditions:Blood Cancer, Women's Studies, Anemia, Hematology
Therapuetic Areas:Hematology, Oncology, Reproductive
Healthy:No
Age Range:Any
Updated:7/1/2018
Start Date:February 2007

Use our guide to learn which trials are right for you!

Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study

This phase II trial studies how well total-body irradiation (TBI) works when given together
with fludarabine phosphate and cyclophosphamide followed by donor bone marrow transplant,
mycophenolate mofetil, and cyclosporine in treating patients with Fanconi anemia (FA). Giving
low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and TBI before
or after a donor bone marrow transplant helps stop the growth of abnormal cells. It may also
stop the patient's immune system from rejecting the donor's stem cells. The donated stem
cells may replace the patient's immune cells and help destroy any remaining cancer cells
(graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
immune response against the body's normal cells. Giving mycophenolate mofetil and
cyclosporine after the transplant may stop this from happening.

PRIMARY OBJECTIVES:

I. Identify doses of total-body irradiation (TBI) that lead to sufficient probability of
donor engraftment (> 5% donor cluster of differentiation [CD]3 chimerism) by day +200.

II. Evaluate the probability of severe acute graft-versus-host disease.

SECONDARY OBJECTIVES:

I. Evaluate the probabilities of overall survival, regimen-related toxicity (RRT), and
recurrent hematopoietic malignancy in those patients with a prior underlying history of such.

II. Examine the degree to which mixed chimerism provides for amelioration of symptoms (i.e.,
infections due to neutropenia, hemorrhage due to thrombocytopenia) associated with bone
marrow failure.

III. Determine if the FA complementation group and % initial mosaicism predict engraftment
and RRT outcomes.

OUTLINE: Patients are assigned to 1 of 4 treatment arms.

NOTE: Patients no longer receive pre-transplant cyclophosphamide as of February 2009.

After completion of study treatment, patients are followed up at 6 months and then annually
thereafter.

Inclusion Criteria:

- Any patient with FA and bone marrow (BM) failure involving 2 of the following 3
lineages: granulocyte count < 0.5 x 10^9/L, platelet count < 20 x 10^9/L, or
hemoglobin < 8 g/dL

- Any patient with FA who requires red blood cell or platelet transfusions because of
marrow failure

- Any patient with FA who has a life-threatening BM failure involving a single
hematopoietic lineage

- Any patient with FA and pre-existing cytogenetic abnormality including hematopoietic
malignancy (acute myeloid leukemia [AML] or myelodysplastic syndrome [MDS]) in
morphological remission (defined as absence of circulating blasts and bone marrow
blasts < 5% as assessed by morphology); Note that hematopoietic recovery is not
required for remission status

- Patients must have a negative cytotoxic cross match with donor

- DONOR: Related, human leukocyte antigen (HLA)-haploidentical donors must be identical
for one HLA haplotype and mismatched for any number of HLA-A, -B, -C, DRB1 or DQB1
loci of the unshared haplotype

- DONOR: Unrelated, HLA-matched donors must be matched at HLA-A, B, C, DRB1 and DQB1 by
deoxyribonucleic acid (DNA) typing at the highest resolution routinely available at
the time of donor selection; a single allele mismatch at HLA-A, B, or C is allowed OR
a single DQB1 mismatch is allowed

- DONOR: Bone marrow will be the only allowed hematopoietic stem cell source

- DONOR: Haploidentical donor selection will be based on standard institutional
criteria, otherwise no specific prioritization will be made amongst the suitable
available donors

Exclusion Criteria:

- Patients having available HLA-matched related donors

- Significant organ dysfunction that would prevent compliance with conditioning,
graft-versus-host disease (GVHD) prophylaxis, or would severely limit the probability
of survival, such as liver disease/failure (active hepatitis, moderate to severe
portal fibrosis/cirrhosis confirmed by biopsy or uncorrectable hepatic synthetic
dysfunction), lung disease, or cardiac disease (ejection fraction < 35%, or if unable
to obtain ejection fraction, shortening fraction of < 26%; if shortening is < 26% a
cardiology consult is required with principal investigator [PI] having final approval
of eligibility)

- Human immunodeficiency virus (HIV) seropositive patients

- Fertile females who are unwilling to use contraceptive techniques during and for the
twelve months following treatment, as well as females who are pregnant or actively
breast feeding

- Fertile males who are unwilling to use contraceptive techniques during and for the
twelve months following treatment

- AML/MDS in morphological relapse, defined as having circulating blasts or bone marrow
blasts >= 5% as assessed by morphology

- Active infectious disease concerns

- Karnofsky performance score < 50 or Lansky performance score < 40

- DONOR: Donors found to have Fanconi anemia based on chromosomal breakage analysis

- DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1
x 10^8 nucleated cells/kg recipient ideal body weight [IBW]) or who are unwilling to
be bone marrow donors

- DONOR: HIV-positive donors

- DONOR: Donors who are cross-match positive with recipient

- DONOR: Recipient homozygous at mismatched locus; if the recipient is homozygous at
HLA-A, B, or C and the donor is mismatched at that locus, the donor should be avoided;
exceptions must be discussed with the PI
We found this trial at
5
sites
747 52nd St
Oakland, California 94609
(510) 428-3000
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
?
mi
from
Oakland, CA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Curitiba, Paraná 80060
?
mi
from
Curitiba,
Click here to add this to my saved trials
9000 W Wisconsin Ave #270
Milwaukee, Wisconsin 53226
(414) 266-2000
Children's Hospital of Wisconsin Nothing matters more than our children. At Children's Hospital of Wisconsin,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials